Last 1,471 GBp
Change Today +6.50 / 0.44%
Volume 1.3M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:21 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

980 Great West Road

Brentford, TW8 9GS

United Kingdom

Phone: 44 20 8047 5000

Fax:

GlaxoSmithKline plc, a healthcare company, researches and develops products in the areas of pharmaceuticals, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The company has a commercial presence in approximately 150 markets, a network of 86 manufacturing sites in 36 countries and research and development centers in the U.K., USA, Spain, Belgium and China. Segments The company operates in the following segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Pharmaceuticals: The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Vaccines: The Vaccines segment produces paediatric and adult vaccines against a range of infectious diseases. In 2013, the company distributed approximately 860 million doses to 170 countries, of which approximately 80% were supplied to developing countries. Consumer Healthcare: The company develops and markets a range of consumer healthcare products. It has brands in four main categories: Total Wellness, Oral Care, Nutrition and Skin Health. These include brands, such as Sensodyne, Panadol and Horlicks. Research and Development In 2013, the company spent £3.9 billion in total, in search to develop innovative medicines, vaccines and consumer products. Competition The company’s main consumer healthcare competitors include Colgate-Palmolive, Johnson & Johnson, Procter & Gamble, Reckitt Benckiser, Unilever, Pfizer and Novartis. Its principal research-based pharmaceutical and vaccines competitors include AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, NovoNordisk, Pfizer, Roche Holdings, Sanofi and Takeda. Significant Events In April 2014, GlaxoSmithkline Consumer Healthcare Ltd. announced that GSK Plc and Novartis AG have entered into an agreement to create Consumer Healthcare Joint Venture to hold GSK's Consumer Healthcare business and Novartis OTC Consumer Healthcare business. In June 2014, Adaptimmune entered into a strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise Adaptimmune's NY-ESO-1 clinical cancer programme. In June 2014, GlaxoSmithKline and ViV Healthcare has teamed up with Janssen R&D Ireland to develop and commercialize a single-tablet dose of an HIV treatment. In June 2014, Cepheid announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals Inc. and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. In September 2014, GE Healthcare announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. In October 2014, Five Prime Therapeutics, Inc. announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease (COPD). In November 2014, Clovis Oncology (CLVS) and GlaxoSmithKline (GSK) announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in the first half of 2015. History GlaxoSmithKline plc was founded in 1935.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:LN 1,471.00 GBp +6.50

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.31 USD +0.25
AbbVie Inc $68.70 USD +0.64
Bayer AG €119.80 EUR +1.98
Celgene Corp $112.61 USD +1.54
Novo Nordisk A/S kr269.50 DKK +2.50
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 16.6x
Price/Sales 2.9x
Price/Book 13.6x
Price/Cash Flow 16.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.